Lifetime pharma ban for 'egregious' and 'dangerous' Shkreli

18 January 2022
federal_trade_commission_big

So-called ‘pharma bro’ Martin Shkreli has been held liable for antitrust claims brought by the US Federal Trade Commission (FTC) and a group of seven state enforcers.

The former pharmaceutical executive and hedge fund manager has been called ‘the most hated man in America’ for price gouging while chief executive of Turing Pharmaceuticals, as well as the ‘pharma bro’ for his social media antics and penchant for hip hop music.

"A significant victory for American consumers"In 2017, Mr Shkreli was convicted on three of eight counts in a month-long securities fraud trial at the US District Court in Brooklyn, New York. This related to allegations of defrauding investors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical